GlassScriptPhysician profile
Adam Thomas Kaul
NPI 1689653107
$19,704.14
in general payments reported to CMS, 2019-2025
19 companies · $1,247 in 2025
The $1,247 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,218 · 2020: $714 · 2021: $1,378 · 2022: $7,468 · 2023: $6,803 · 2024: $876 · 2025: $1,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,714 · Food and Beverage: $4,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,713.98 |
| Food and Beverage | $4,212.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $6,888.89 | 2019-2023 | Aristada, Lybalvi |
| Neuronetics, INC. | $5,843.51 | 2021-2023 | Neurostar Tms Therapy System |
| Neurocrine Biosciences, INC. | $1,371.85 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $1,107.99 | 2019-2021 | |
| Abbvie INC. | $856.71 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $803.69 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $790.48 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $447.70 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $281.37 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $267.40 | 2021-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $263.92 | 2019-2020 | |
| Lundbeck LLC | $260.60 | 2020-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $229.78 | 2019-2025 | Invega Sustenna, Invega, Spravato |
| Avanir Pharmaceuticals, INC. | $116.18 | 2019-2022 | |
| Eisai INC. | $116.00 | 2020-2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $23.02 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.93 | 2022 | |
| Merck Sharp & Dohme LLC | $12.75 | 2021 | |
| Sumitomo Pharma America, INC. | $3.37 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Kaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.